Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01194856 · ClinicalTrials.gov registry record · Phase 4
Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression
A Phase 4 study, sponsored by The Cleveland Clinic.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT01194856 is a Phase 4 study that was terminated before completion, run by The Cleveland Clinic. The registered enrollment target is 1 participants.
The verdict
NCT01194856, a Phase 4 study, was terminated before completion, sponsored by The Cleveland Clinic.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purposes of this study are to evaluate if switching an antiretroviral medication from efavirenz (EFV) to atazanavir/ ritonavir (ARV/r) will, in a 96-week period, change: 1. the amount of fat in HIV patients with lipoatrophy, 2. metabolic lab values such as your lipid (fat) profile, glucose (blood sugar), and insulin (a hormone that regulates glucose) in HIV patients with lipoatrophy.
Interventions
- DRUG Efavirenz
- DRUG Atazanavir/ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2010-10 |
| Est. Completion | 2011-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01194856
The ClinicalTrials.gov registry entry for NCT01194856 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Efavirenz is the first listed.
NCT01194856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01194856 about?
NCT01194856 is a clinical study titled "Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression". The purposes of this study are to evaluate if switching an antiretroviral medication from efavirenz (EFV) to atazanavir/ ritonavir (ARV/r) will, in a 96-week period, change: 1. the amount of fat in HIV patients with lipoatrophy, 2. metabolic lab values such as your lipid (fat) profile, glucose (blo...
What is the current status of trial NCT01194856?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2010-10. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01194856?
The interventions under investigation include: Efavirenz (DRUG), Atazanavir/ritonavir (DRUG).
Who is sponsoring clinical trial NCT01194856?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.